GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anebulo Pharmaceuticals Inc (NAS:ANEB) » Definitions » Equity-to-Asset

Anebulo Pharmaceuticals (Anebulo Pharmaceuticals) Equity-to-Asset : 0.87 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Anebulo Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Anebulo Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $6.49 Mil. Anebulo Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $7.50 Mil.

The historical rank and industry rank for Anebulo Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

ANEB' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.2   Med: 0.92   Max: 1
Current: 0.87

During the past 4 years, the highest Equity to Asset Ratio of Anebulo Pharmaceuticals was 1.00. The lowest was -2.20. And the median was 0.92.

ANEB's Equity-to-Asset is ranked better than
80.01% of 1566 companies
in the Biotechnology industry
Industry Median: 0.66 vs ANEB: 0.87

Anebulo Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for Anebulo Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anebulo Pharmaceuticals Equity-to-Asset Chart

Anebulo Pharmaceuticals Annual Data
Trend Jun20 Jun21 Jun22 Jun23
Equity-to-Asset
-0.06 0.99 0.97 0.91

Anebulo Pharmaceuticals Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.92 0.90 0.91 0.92 0.87

Competitive Comparison of Anebulo Pharmaceuticals's Equity-to-Asset

For the Biotechnology subindustry, Anebulo Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anebulo Pharmaceuticals's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anebulo Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Anebulo Pharmaceuticals's Equity-to-Asset falls into.



Anebulo Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Anebulo Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Equity to Asset (A: Jun. 2023 )=Total Stockholders Equity/Total Assets
=10.601/11.67
=

Anebulo Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=6.487/7.501
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anebulo Pharmaceuticals  (NAS:ANEB) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Anebulo Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Anebulo Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Anebulo Pharmaceuticals (Anebulo Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
Executives
Bimal R. Shah director C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTER AVENUE, SUITE 240, HENDERSON NV 89052
Richard Anthony Cunningham, director, officer: Chief Executive Officer ONE KENDALL SQUARE, BUILDING 200 SUITE 2, CAMBRIDGE MA 02139
Dan George officer: Chief Financial Officer 1412 62ND STREET, EMERYVILLE CA 94608
Sandra A. Gardiner officer: Acting Chief Financial Officer CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Kenneth C Cundy officer: Chief Scientific Officer 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Nathaniel Calloway director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Simon Allen director, officer: Chief Executive Officer C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Aron R. English director, 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Kenneth Lin director PO BOX 1005, LOS ALTOS CA 94022
Karah Herdman Parschauer director 60 LEVERONI COURT, NOVATO CA 94949
22nw Fund, Lp 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Joseph F. Lawler director, 10 percent owner 2110 RANCH ROAD 620 S, #341732, LAKEWAY TX 78734
Areta Kupchyk director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Jason Aryeh director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
22nw, Lp 10 percent owner, other: See Explanation of Response 590 1ST AVE S, UNIT C1, SEATTLE WA 98104

Anebulo Pharmaceuticals (Anebulo Pharmaceuticals) Headlines

From GuruFocus

Anebulo Pharmaceuticals Announces New CEO

By Business Wire 10-06-2023